Human medicines European public assessment report (EPAR): Insulin aspart Sanofi, insulin aspart, Date of authorisation: 25/06/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 18, Status: Authorised

Union Product Database

Human medicines European public assessment report (EPAR): ellaOne, ulipristal acetate, Date of authorisation: 15/05/2009, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Caprelsa, vandetanib, Date of authorisation: 16/02/2012, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Pravafenix, fenofibrate,pravastatin, Date of authorisation: 14/04/2011, Revision: 10, Status: Authorised

Agenda - Information session on the pilot for expert panels' advice for orphan medical devices

Scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the list of substances essential for the treatment of equine species and for which the withdrawal period for equine species shall be six months

Human medicines European public assessment report (EPAR): Amsparity, adalimumab, Date of authorisation: 13/02/2020, Revision: 6, Status: Authorised

Q&A clinic on Product Management Service (PMS) Product User Interface (PUI) and Application Programming Interface (API) - 22 October 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 22 October 2024, 10:00 (CEST) to 22 October 2024, 10:30 (CEST)